Nanoparticles made of polylactide-poly(ethylene glycol) block-copolymer (PLA-PEG) are promising vehicles for drug delivery due to their biodegradability and controllable payload release. However, published data on the drug delivery properties of PLA-PEG nanoparticles are heterogeneous in terms of nanoparticle characteristics and mostly refer to low injected doses (a few mg nanoparticles per kg body weight). We have performed a comprehensive study of the biodistribution of nanoparticle formulations based on PLA-PEG nanoparticles of 100 nm size at injected doses of 30 to 140 mg/kg body weight in healthy rats and nude tumor-bearing mice. Nanoparticle formulations differed by surface PEG coverage and by release kinetics of the encapsulated model active pharmaceutical ingredient (API).
Comprehensive study of the drug delivery properties of poly(L-lactide)-poly (ethylene glycol) nanoparticles in rats and tumor-bearing mice 
Introduction
In recent decades there has been a definitive shift of the pharmaceutical paradigm from the use of individual active pharmacological ingredient (API) molecules delivered in "free form" (in simple formulations aiming to directly dissolve the API in the bodily fluids) towards supramolecular systems like liposomes, micelles and nanoparticles, especially in the field of oncology [1] [2] [3] . The drug delivery system acts as a carrier for the API and alters its biodistribution and pharmacokinetics, while the API itself is only responsible for the therapeutic activity. Therefore, the pharmacokinetics of an encapsulated API formulation can change drastically compared to a traditionally formulated API, thereby altering therapeutic and toxic effects. For example, nanoparticles normally only exit the circulation in sites where the integrity of capillary walls is incomplete (such as in the liver) or compromised, such as in inflamed tissues and malignant tumors [4] . Such selective accumulation, called enhanced permeability and retention (EPR), ensures locally elevated and sustained concentration of released API and promotes therapy. The absence of sharp peak concentration of free API in systemic circulation may suppress acute toxicity, while accumulation in healthy organs like liver and spleen can promote nanoparticle-specific local toxicity.
It is well known that variables such as particle size and surface properties influence the biodistribution of nanocarriers [5] [6] [7] . The majority of fundamental studies on the influence of these factors has been carried out either with liposomes, which are less stable and provide less controllable API release than nanoparticles, or with nanoparticles prepared from non-biodegradable materials, such as gold, silica or polystyrene [5] . These offer a broader range of size and surface engineering possibilities than biodegradable nanoparticles, but have less potential as platforms for drug delivery systems because of greater risks of long-term accumulation in the tissues leading to toxic effects [8] .
Of biodegradable nanoparticles, poly(lactide-co-glycolide) (PLGA) and polylactide (PLA) nanoparticles bear particular promise [9] , especially when prepared from block-copolymers with polyethylene glycol (PLGA-PEG or PLA-PEG, respectively). The hydrophobic PLA/PLGA core can encapsulate the API and ensure reproducible release kinetics, while the PEG layer provides "stealth" properties to the nanoparticle. ACCURINS® are polymeric nanoparticles based on PLA-PEG developed at BIND Therapeutics Inc. ACCURINS® can be administered in a wide range of doses, and Accurin technology was shown to be capable of high-efficiency encapsulation and finely-tuned controllable release of diverse APIs [10] [11] [12] .
This manuscript is focused on studies to further the in-depth understanding of the biodistribution of PLA-PEG nanoparticles. Studies of PLA-PEG and PLGA-PEG nanoparticle biodistribution have been reported before, but are a heterogeneous body of data, mostly consisting of studies where only a single dose level on the order of a few mg nanoparticle material/kg body weight was studied [13] . In therapeutic applications, such dose ranges would only be relevant for APIs having therapeutic activity at μg-per-kg doses. Moreover, with drug-loaded nanoparticles, distribution of the drug and the nanoparticles was rarely assessed independently.
We have studied the influence of release kinetics, PEG coverage and injected dose on the distribution of a model API (vincristine) encapsulated into PLA-PEG nanoparticles. We have also developed a physiologically based pharmacokinetic (PBPK) model to describe the distribution of an API encapsulated in a nanoparticle formulation with a release rate designed for therapeutic applications.
Materials and methods

Materials and reagents
PLA/PEG block-copolymers with number-average molecular weights of approximately 16, 30 and 50 kDa for PLA and approximately 5 kDa for PEG were received from Evonik (part #100 DL mPEG 5000 3.5 CE). Acetonitrile, ethyl acetate (EA), benzyl alcohol (BA), trifluoroacetic acid (TFA), dimethylsulfoxide (DMSO), heptane, methyl tert-butyl ether (MTBE), RPMI-1640, Dulbecco's phosphate buffered saline (DPBS), gentamicin, and Hoechst 33342 were from the local supplier.
Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) was from Novabiochem (EMD). Diisopropyl ethylamine (DIEA), pamoic acid, decanoic acid, sodium cholate, Brij ® S-100, formaldehyde solution, and phorbol 12-myristate 13-acetate (PMA) were from Sigma-Aldrich Ltd. (St. Louis, MO, USA). Tween® 80 and urea (Panreac®, Spain), fetal bovine serum (FBS, Hyclone), bovine serum albumin (BSA, AppliChem), TrypLE Express Enzyme® (Thermo Fisher Scientific), Matrigel® Basement Membrane Matrix (Corning Inc).
VCR base was provided by Chongqing Chinabase Import & Export Co, Ltd. (Chongqing, China). VCR sulphate was from Teva. Cy5-amine and 10 kDa PLA-COOH were from Lumiprobe and Durect Corporation (Cupertino, USA), respectively. All reagents were analytical or highperformance liquid chromatography (HPLC) grade and were used without further purification.
Synthesis of PLA-Cy5 conjugate
10 kDa PLA-COOH (1 g, 0.1 mmol) was dissolved in 10 ml DMSO for a final concentration of 100 mg/ml. To this was added Cy5-Amine (0.058 g, 0.1 mmol), PyBOP (0.052 g, 0.1 mmol), and DIEA (0.087 ml, 0.5 mmol). The coupling reaction was monitored by LCMS, where the transfer of Cy5 optical properties (650 nm absorbance) to the hydrophobic polymer could be observed. Upon completion, the polymer product was purified by precipitation in 20% heptane in MBTE. The resulting precipitate was filtered off, washed with 20% heptane in MBTE and dried to give a dark blue solid. The purified product was characterized by LCMS (results are presented in the Supplementary material).
Nanoparticle preparation procedure
Nanoparticles were prepared by a single-emulsion method as described in the literature [11, 14, 15] . Briefly, PLA/PEG-polymers of varying molecular weight dependent on the formulation, excipient (if needed) and VCR were dissolved in a water-immiscible solvent (e.g. a mixture of EA and BA) to obtain an organic phase. Excipients added into the organic phase allow the modification of the release kinetics of investigated formulations. The organic phase was then rapidly combined with a cooled aqueous phase containing a surfactant to form coarse emulsion. The coarse emulsion was subsequently emulsified either with a high-pressure microfluidizer (Lab Homogenizer M-110P, Microfluidics, Inc., Westwood, MA, US) at 10 kPa or by probe sonication using a custom-made ultrasound generator (frequency -40 kHz, power -300 W, probe diameter -5 mm) at maximum power under ice cooling. The organic/aqueous fine nanoemulsion was collected and poured into cold water to extract organic solvents and non-encapsulated drug and harden the nanoparticles. In order to solubilize non-encapsulated payload a solution of Tween® 80 (35% w/w; 25:1-Tween to payload ratio) was added to the final solution under stirring. Obtained nanoparticles were concentrated and diafiltered into DI water with tangential flow ultrafiltration/diafiltration (Biomax® 300 kDa, Millipore, US). Nanoparticles were stored as a frozen suspension in a 10% aqueous sucrose solution for stabilization and cryopreservation of the nanoparticle suspension [10] .
Nanoparticle characterization
Nanoparticle formulations were characterized with respect to particle size, drug load and in vitro release (IVR) profiles.
Size and polydispersity analysis
Particle size distribution was measured in dilute aqueous suspension using dynamic light scattering (DLS) with Nano S-90 instrument (Malvern, UK) using a 633 nm laser scattered at 90°in a low-volume polystyrene cuvette placed in thermostated sample chamber set to 25°C. Results are reported as z-average diameter. Each sample was measured in triplicate to ensure reproducibility.
Total and surface PEG analysis
Analysis was performed using the approach described by Hrkach et al. [16] . Suspensions of nanoparticles were concentrated tõ 100 mg/ml by centrifugal ultrafiltration through 100 kDa membranes. Then suspensions were diluted with D 2 O at 1:1 volume ratio and concentrated back 100 mg/ml or by centrifugal ultrafiltration (30-40 min at 1700 g). D 2 O dilution-ultrafiltration cycles were repeated until > 98% of the original water in the suspension were replaced with D 2 O. Aliquots of the resulting suspensions were then evaporated in vacuo and residues were dissolved in chloroform-d. Proportional amounts of dimethyl formamide were added to D 2 O suspensions and chlorofom-d solutions to act as internal standards, so that mass ratios of polymer to DMF were equal in all solutions and suspensions.
Proton NMR spectra were acquired using a 300 MHz Bruker AM300 spectrometer. The spectra were analyzed and integrated in Mestrenova software (Mestrelab Research). Calculations of the fractions of total and surface PEG are described in the Supplementary material.
Payload content analysis
Total solid concentration in nanoparticle suspension was determined by gravimetric drying of an aliquot of the concentrated nanoparticle suspension (prior to adding the cryoprotectant) in a vacuum oven at 80°C. VCR content in nanoparticles was analyzed by UV-UPLC (Acquity, Waters, US) at 296 nm in water-acetonitrile gradient with 0.016-0.02% v/v trifluoroacetic acid using C8 reverse phase column (Acquity UPLC BEH C8, 2.1 × 100 MW, 1,7 μm, Waters, US) at 40°C and eluent flow rate 500 μl/min. Gradient conditions can be found in the Supplementary Material. The aliquot of nanoparticle suspension was dissolved in 50% acetonitrile and assayed as described. VCR loading in weight percent (wt%) was calculated using the following equation:
where L is the drug loading, C D is the drug (VCR) concentration and S is the total solids concentration in the nanoparticle suspension.
PLA-Cy5 content in nanoparticles was not measured experimentally, but visual examination of the tangential flow filtration procedure suggested that virtually all PLA-Cy5 was encapsulated.
Payload release profile
VCR release kinetics were determined in vitro under physiological sink conditions. Nanoparticles were suspended in 0.01 M phosphate buffered saline (pH 7.4) containing 10% w/w of urea at concentration corresponding to approximately 20 μg/ml of loaded drug and incubated with mild agitation in a 37°C water bath. At 0, 1, 4, 24, 48, 72 and 96 h time points an aliquots of suspensions were taken and divided into two parts. One part was centrifuged for 30 min at 657000 g at 4°C (Optima™MAX-XP centrifuge, Beckman Coulter, US) to precipitate undissolved particles, and supernatant was analyzed for released VCR concentration (C i CNTR ) using UPLC method described previously. The other part was analyzed by UPLC without centrifugation to obtain total VCR concentration in the probe (C i NC ). All release experiments were repeated three times. The percentage of released drug (Rel) was calculated as:
PLA-Cy5 release kinetics were determined using the same approach as described above, with the following modifications: nanoparticles were suspended in 2% polysorbate 80 in phosphate buffered saline (PBS) and withdrawn aliquots of the suspension were centrifuged at 657,000 g for 30 min. Samples of the supernatant and the intact suspension were analyzed by fluorimetry (ex 650 nm, em 670 nm).
Release half-lives
To estimate release half-lives for VCR nanoparticle formulations (the amount of time necessary for the release of 50% of encapsulated drug), the amounts of released VCR were recalculated into the amounts of retained VCR:
where Ret i and Rel i are, respectively, amounts of retained and released VCR (in %) at the i-th timepoint, and Rel 0 is the amount of released drug at time zero. Release half-lives were then obtained by fitting a monoexponential decay function on the resulting array of Ret i values for different timepoints using weighted non-linear least squares approach. Ret i data points were assigned weights equal to 1/Ret i . Fitting was performed using the Solver Add-In in Microsoft Excel.
In vitro experiments
The methods of cell culturing and measurement of nanoparticle uptake by macrophages in vitro are described in the Supplementary material. All animals were provided ad libitum access to water and standard laboratory chow.
Pharmacokinetics in rats and mice
Rats (5 per tested formulation, 250 ± 20 g body weight) with catheters implanted into their jugular veins were administered VCRloaded nanoparticle formulations (A, C, E or F) at the dose of 0.5 mg/kg VCR into their lateral tail veins (injection volume 1.0 ml/kg). Blood samples of 200 μl were collected through the catheters before the injection and at 5 min, 30 min, 2, 4, 8, 24 and 48 h post-injection. After that rats were euthanized in the CO 2 chamber and bled by cardiac puncture.
Mice (8 per tested formulation, 22 ± 5 g body weight) received VCR-loaded nanoparticle formulations at doses of 0.5 mg/kg VCR (formulations B, D, E, G) or 1.0 mg/kg VCR (formulations A, C) into the lateral tail vein (injection volume 10 ml/kg). Blood samples were obtained for the following timepoints 5 min, 30 min, 2, 4 and 24 h postinjection. From each mouse, three blood samples were collected: two by bleeding the facial vein on each cheek, and one by cardiac puncture right after euthanasia in the CO 2 chamber. The set of timepoints for blood sample withdrawal was chosen randomly for each mouse so as to obtain 3-4 different blood samples from different mice for each timepoint.
Blood samples were collected into lithium heparin tubes and centrifuged for 5 min at 7000 g to obtain plasma. Plasma was stored at − 80°C until analysis. VCR content was determined by UV-HPLC as described below.
Biodistribution studies in mice
Mice were subcutaneously inoculated in the right flank with 200 μl of 10 6 MX-1 cells resuspended in 50% growth medium and 50%
Matrigel®. Tumor volumes were measured with caliper every 3-5 days from day 5 post-inoculation to follow the development of tumors. Tumor volumes were calculated from caliper measurements as:
Nanoparticles (30, 70 or 140 mg/kg) or VCR sulphate (1.5 or 3 mg/kg of VCR base) were injected into the lateral tail vein (injection volume 10 ml/kg). At pre-determined timepoint post-injection (2, 6, 24 or 48 h) mice were weighed, euthanized in the CO 2 chamber and bled by cardiac puncture. Plasma was obtained as described in the pharmacokinetics section. Organs were excised and put into pre-weighed Eppendorf tubes. All biological samples were stored at − 80°C until analysis. Individual changes in body weight (at euthanasia vs before injection) were calculated in %.
Summary of performed biodistribution experiments is presented in Table 1 .
Bioanalysis of VCR content in animal tissues and plasma
Biological samples stored at − 80°C were thawn at r.t. and subsamples of 30-50 mg were transferred into homogenization vials with zirconium oxide beads (CK14-0.5, Precellys). To each sample was added a pre-determined amount (4 ml/g) of 50% acetonitrile with vinblastine as internal standard. Samples were homogenized by vigorously shaking for 60-120 s using Minilys homogenizer (Precellys) at max speed and centrifuged for 5 min at 7000 g. Aliquots of supernatant (50 μl) were mixed with liquid-liquid extraction buffer (100 mM NaClO 4 , 900 mM ammonia) at 3/4 v/v ratio and applied to Isolute SLE + supported liquid extraction cartridges (Biotage). The cartridges were eluted with 0.5 ml portions of ethyl acetate, eluate was evaporated to dryness in vacuo, the residues were redissolved in 100 μl aliquots of HPLC eluent and by UV-UPLC as described in drug loading analysis. Concentrations of vincrinstine in tissues were determined using 5-7-point calibration curves prepared from "empty" samples of appropriate mouse tissues with known amounts of VCR added before homogenization.
Bioanalysis of VCR in mouse and rat plasma was carried out in the same fashion, but without the homogenization step; aliquots of plasma were directly mixed with liquid-liquid extraction buffer containing internal standard.
Processing of VCR concentration data
Plasma and tissue concentrations of VCR obtained in the biodistribution experiments were recalculated into percentages of injected dose per gram tissue (%ID/g) as:
Note that μg/g concentration units and mg/kg dose units are equivalent to each other. The animal weight in Eq. (5) refers to the moment of injection. For all tissues except plasma, fractions of injected dose accumulated in the whole organ (or whole tumor) were also calculated as:
All data are presented as means ± standard deviations.
Processing of pharmacokinetic data
The values of plasma half-life and distribution volume at the moment of injection (V d0 ) for the investigated formulations were estimated by fitting a mono-exponential decay function, C(t) = C 0 e -kt , on the pool of plasma concentration values for different timepoints using weighted non-linear least squares approach.
Plasma half-life was calculated as:
where k is the fitted value of the elimination constant (in h
). Volume of distribution was calculated as:
where C 0 is the fitted value of the plasma VCR concentration at the moment of injection (g/ml), while ID is the injected VCR dose (in g/kg body weight).
In rat data, where 7 datapoints per animal were available, T 1/2 and V d0 values were estimated separately for individual animals and then averaged. In mouse data, T 1/2 and V d0 values were estimated from composite pharmacokinetic curves including data for all mice injected with a given formulation at a given dose. Experimental concentration values were assigned weights equal to the inverse of their values. Fitting was performed using the Solver Add-In in Microsoft Excel (for rats) and GraphPad Prism 6 software (for mice).
PBPK modelling
The mathematical modelling approach is described in detail in the Supplementary Material. The PBPK model described absolute concentrations of VCR and nanoparticles in plasma and tissues.
Results and discussion
Synthesis and characterization of drug and fluorescent dye-loaded nanoparticles
The aim of this work was to obtain a comprehensive and coherent dataset characterizing PLA-PEG nanoparticles as a drug delivery vehicle. Our primary focus lay on in vivo organ-scale biodistribution of nanoparticles and encapsulated drug. For this purpose, we prepared nanoparticle formulations loaded with a model drug -vincristine (VCR) -and having different release rates. In formulations with the slowest release, VCR was effectively used as a probe to follow the distribution of nanoparticles in vivo. In order to follow nanoparticles in vitro on a cellular scale, we also prepared fluorescently labeled nanoparticles by encapsulating a conjugate of the far-red fluorescent dye Cy5 with 10 kDa PLA. The full list of prepared nanoparticle formulations is presented in Table 2 .
All nanoparticles were prepared using a single-emulsion approach (see Methods). VCR was encapsulated to 6 ± 3 wt% by an in situ hydrophobic ion pairing approach using hydrophobic acids as counterions as described by Song et al. [11] . Hydrophobicity and ionizability of VCR make it a convenient material for such encapsulation method. VCR-loaded nanoparticles had release kinetics varying from what we designated 'ultra-slow' (< 10 wt% cumulative payload released over 72 h for formulations U16c and U16p, see Table S1 ) to 'fast' (50% payload released over 5 h for baseline formulation A, see Fig. 1A ). a To ensure that obtained biodistribution trends are not formulation-specific, two formulations (U16c and U16p) were used to study the biodistribution of 16/5 nanoparticles. Half of the animals in each group were treated with formulation U16c, while another half were treated with formulation U16p.
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Fluorescent PLA-Cy5 conjugate was encapsulated into the nanoparticles to 2 wt%. The PLA part of the conjugate acted as an anchor, trapping Cy5 inside the core of the nanoparticles and limiting its release to a negligible rate (Table S2 ). All prepared nanoparticles had sizes within a 90-110 nm range. This size is large enough to prevent filtering out by the kidneys, small enough to avoid accumulation in the lungs and is conducive to accumulation in the areas of compromised vasculature due to the EPR effect [4, 17] . The 90-110 nm size range chosen for the nanoparticles also enhances the reproducibility of loadings and release profiles and facilitates sterilization by filtering. This is the size of ACCURINS® currently being evaluated in the clinic [10, 12] . Polydispersity index did not exceed 0.254. 1 H NMR spectroscopy in deuterated chloroform and deuterated water showed that the mass fraction of PEG in the nanoparticles was close to nominal for the used block-copolymers, and almost all of the PEG was exposed on the nanoparticle surface and solvated (Table 3) .
Biodistribution experiments
The main application area for PLA-PEG nanoparticles as drug delivery vehicles is anti-tumor therapy. Therefore our primary focus lay on in vivo organ-scale biodistribution in a human tumor xenograft model in mice. Tumor xenografts were generated in immunodeficient mice with MX-1 breast carcinoma cells, which are known to produce fast-growing vascularized tumors and were used in tumor growth inhibition studies with ACCURINS® [10, 18, 19] .
Influence of release rate on API pharmacokinetics
In order to visualize the relationship between payload API levels in animal tissues and the strength of payload association with the A -in vitro release curves, B -plasma pharmacokinetic curves in rats, C -plasma pharmacokinetic curves in mice, D -correlation plot for in vitro release half-lives and plasma elimination half-lives in rats (circles) and mice (squares); dotted trend lines are drawn manually. Formulations are uniformly color-coded in all panels. Pharmacokinetic curves reflect total (free and encapsulated) VCR concentrations in plasma. nanoparticles, we compared pharmacokinetic profiles for VCR encapsulated into 16/5 PLA-PEG nanoparticles with varying release rates. Independent measurement of nanoparticle-encapsulated and released VCR concentrations in plasma is greatly complicated by the need to separate nanoparticle-encapsulated from plasma protein-bound VCR. Therefore, we monitored total (nanoparticle-encapsulated and released, both free and protein-bound) VCR in the plasma of rats and mice injected with VCR-loaded nanoparticles. Given the large volume of distribution for vincristine [20] and previous experience with high log P payloads [10] , we would expect the majority of these measurements to be nanoparticle-encapsulated VCR. There was visible association between the rate of VCR release from the nanoparticles and the pharmacokinetics of the total VCR in rat and mouse plasma (Fig. 1B-D) : controlled alterations in the release rate of the nanoparticle formulations led to gradual changes in the elimination half-lives calculated from total VCR concentration curves in plasma.
For formulations with release half-lives over~150 h, plasma halflife reached a plateau of about~18 h in rats and about~10 h in mice. These values are in agreement with previously determined half-life of PLA-PEG nanoparticle in rodents [10] and are much greater than halflives reported in the literature for PLA-PEG nanoparticles with higher PLA molecular weight: 2-6 h in rats [21, 22] and 2-7 h for mice [23, 24] .
These results show that when the fraction of payload released over the timeframe of the biodistribution experiment is negligible, the measured concentration of the API can be used as a proxy for nanoparticle concentration.
Nanoparticle biodistribution studied in detail: influence of PEG coverage
Increasing the molecular weight of the hydrophobic polymer forming the nanoparticle core generally leads to slower API release with more reproducible release profiles [25, 26] . However, in PEGylated block copolymers, higher molecular weight of the hydrophobic polymer also means a lower mass percentage of PEG. For nanoparticles of a constant size, lower mass percentage of PEG leads to decreased PEG coating on the surface, which can result in opsonization and a decrease in circulation time [27] .
We compared the biodistribution of ultra slow releasing VCR-loaded 100 nm nanoparticles prepared with 16/5, 30/5 or 50/5 PLA-PEG in MX-1 tumor-bearing mice. Samples were collected over 48 h post-injection, which corresponds to about 5 estimated plasma half-lives for 16/5 nanoparticles (see above). In order to evaluate the dose-linearity of the tissue pharmacokinetics, three different doses were administered: 30, 70 and 140 mg nanoparticles/kg body weight. Doses were chosen to correspond to the range used in preclinical efficacy studies with ACCURINS® in mice: from~30 mg/kg [19] to~120 mg/kg [10] . It should be noted that empty PLA-PEG nanoparticles themselves were found to be non-toxic at injected doses of up to 850 mg/kg (unpublished data of BIND Therapeutics Inc). VCR concentrations were measured in the plasma, in the organs that can take part in the elimination of the nanoparticles (liver, spleen, lungs) and their debris (kidneys) and in the tumor xenografts.
Up to 11.8 mg/kg of the nanoparticle-formulated VCR was injected into mice, which is 4-fold higher than the LD50 of unencapsulated VCR after intravenous injection in mice (3.0 mg/kg [28] ). However, there were no visible toxicity effects and body weight loss over the course of the experiment did not exceed 7% even at the highest injected dose (Fig. S2) . This confirms that VCR remains encapsulated in the nanoparticles upon injection and does not exert toxic action within the investigated timeframe. Dose-normalized concentration timecourses for 16/5, 30/5 and 50/ 5 nanoparticles in the investigated tissues are presented in Fig. 2 . Nanoparticles of all three types showed gradual elimination from the plasma and lungs and accumulation in spleen, liver and tumor. Kidney levels were stable over the course of the experiment for 16/5 and 30/5 nanoparticles and slowly decreased for 50/5 nanoparticles. In general, the distribution of nanoparticles in all investigated organs was doseindependent in the selected dose range.
Nanoparticles with lower PEG coverage showed accelerated elimination from the bloodstream. Elimination half-lives calculated from the plasma concentration timecourses (measured starting from 2 h postinjection) were 10.3 ± 1.2 h for 16/5 nanoparticles, 7.2 ± 1.4 h for 30/5 and 7.0 ± 0.7 h for 50/5 nanoparticles (here and below: values averaged over the three investigated doses). Average distribution volumes at the moment of injection (V d0 ) were, respectively, 48 ± 2 ml/ kg, 72 ± 16 ml/kg and 172 ± 7 ml/kg body weight. The circulating blood volume in a mouse is about 72 ml/kg [29] ; assuming the hematocrit value of 0.45 (i.e. plasma making up 55% of the blood volume) this gives the circulating plasma volume of 40 ml/kg. Apparently, 16/5 nanoparticles are constrained to the vascular volume for longer than 30/5 and 50/5 nanoparticles, and a considerable proportion of nanoparticles of the latter two types is eliminated from the bloodstream within the first two hours post-injection.
Increased uptake of nanoparticles with lower PEG coverage was pronounced in the spleen. At 24 h post-injection, spleen levels were 19 ± 9%, 34 ± 5% and 82 ± 13% injected dose per gram tissue (% ID/g) for 16/5, 30/5 and 50/5 nanoparticles, respectively. Multiplication of these concentrations by the actual spleen weights (about 0.13 g on average), gives 2.1 ± 1.0%, 4.2 ± 0.6% and 10.8 ± 1.1% injected nanoparticle dose in the whole spleen for the three nanoparticle types. At 48 h post-injection, spleen levels of 50/5 nanoparticles at the highest injected dose were markedly greater than at the lowest injected dose (96 ± 3% vs 43 ± 6% ID/g, respectively). In other words, the normalized uptake of nanoparticles in the spleen appeared to increase with dose. There was no concomitant decrease in the normalized nanoparticle uptake in any other tissue investigated, so this observation cannot be explained by the "spillover" of the nanoparticles from some other tissue, where nanoparticle uptake capabilities have been saturated, into the spleen (unless some tissue beyond those investigated by us is considered). Alternatively, one could hypothesize that nanoparticles stimulated macrophage proliferation in the spleen, creating a positive feedback loop, but literature data on non-PLA nanoparticles suggest exactly the opposite effect [30, 31] .
In the liver, nanoparticle levels at 24 h post-injection were 18 ± 3% ID/g for 16/5, 25 ± 4% ID/g for 30/5 and 17 ± 1% ID/g for 50/5 nanoparticles (21 ± 4%, 33 ± 3% and 23 ± 2% ID per whole liver). The apparent fall in liver uptake for 50/5 nanoparticles compared to 30/5 nanoparticles could reflect the "competition" between nanoparticles' capture by the liver and by the spleen, as the sum of liver and spleen uptake at 24 h post-injection (23% for 16/5, 37% for 30/5 and 34% for 50/5 nanoparticles) increased more monotonously with the fall in PEG coverage than liver uptake alone.
Total nanoparticle levels in the lungs followed plasma concentrations, suggesting high vascular volume (one source reports the vascular volume of 142-235 μl/g for lungs [32] ) and relatively low penetration of nanoparticles into the lung tissue. Across the investigated timepoints, total lung uptake of 50/5 nanoparticles was slightly lower than total lung uptake of 16/5 and 30/5 nanoparticles. However, lung-to-plasma level ratios grew in the order 16/5 < 30/5 < 50/5 (Fig. S3) . Assuming the vascular volume of 185 μl/g and the hematocrit value of 0.45, the "vascular component" can be calculated and substracted from the total nanoparticle concentrations in the lung. Such calculations produced the following estimates of nanoparticle concentrations in the lung tissue excluding blood vessels at 24 h post-injection: 0.80 ± 0.88% ID/g for 16/5, 1.20 ± 0.30% ID/g for 30/5 and 2.22 ± 0.74% ID/g for 50/5 nanoparticles (0.13 ± 0.14%, 0.17 ± 0.03% and 0.28 ± 0.16% ID in all lung tissue). These results suggest that nanoparticles with lower PEG coverage were more strongly retained in the lungs than nanoparticles with higher PEG coverage.
Greater vulnerability of nanoparticles with lower PEG coverage to uptake by immune cells was also confirmed in vitro with PLA-Cy5 labeled nanoparticles. The intensity of nanoparticle capture by macrophages induced from THP-1 monocytes rose as the PEG coverage of nanoparticles fell (Fig. S4) , which is also consistent with previous reports on PLA-PEG nanoparticle interaction with mouse macrophages [33] .
The accumulation of nanoparticles in the MX-1 tumors was approximately equal for 16/5 and 30/5 and lower for 50/5 nanoparticles. Tumor concentrations at 48 h post-injection were 4.7 ± 1.3%, correlation between the tumor size and tumor uptake could be observed for any nanoparticle type (Fig. S5) .
The total fraction of injected dose found in the six investigated tissues (Fig. S6) decreased with time for all nanoparticle formulations. Between 2 and 48 h post-injection, it fell from 85% to 27% for 16/5 nanoparticles, from 68% to 38% for 30/5 and from 44% to 37% for 50/ 5 (values calculated on the assumption that circulating plasma volume in mice is 40 ml/kg). Therefore, by 48 h post-injection, two-thirds to three-quarters of injected dose distributed to organs and tissues beyond the ones investigated by us. Literature data for polymeric nanoparticles, although non-biodegradable ones, show that only a few percent of injected nanoparticles get excreted from rodents within 2 days post- %ID/g Fig. 3 . Biodistribution of formulations U16c/p, T and convensional VCR sulphate in MX-1 tumor-bearing mice. Uptake timecourses for nanoparticle formulations are shown for injected doses of 30, 70 and 140 mg nanoparticles per kg body weight (blue, orange and grey lines in left and middle columns). Uptake timecourses for VCR sulphate are shown for injected doses of 1.5 and 3 mg/kg (blue and orange lines in the right column). All uptake data are recalculated into % injected dose per gram tissue. Points represent group means, error bars represent standard deviations. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) injection [34, 35] , so excretion of nanoparticles within the timeframe of our experiment is most likely to be negligible.
The use of ultra-slow release VCR-loaded and PLA-Cy5-loaded nanoparticles has allowed us to demonstrate the differences in the biodistribution patterns of nanoparticles with varying PEG coverage in vivo and investigate the factors underlying those differences in vitro. 16/5 PLA-PEG polymer demonstrated the highest "stealth" properties, therefore all further work was performed with nanoparticles made from this polymer.
Relationship between payload and nanoparticle biodistribution
The biodistribution of a drug encapsulated into nanoparticles or nanocarriers is determined by many factors, such as the kinetics of nanocarrier and drug distribution between plasma and tissues the kinetics of drug release from the nanocarrier [36] . For a therapeutic formulation, the effect of the released drug on the physiology of the test subject can also be an important factor influencing the kinetics of both nanoparticle and encapsulated drug distribution in tissues. For example, released drug may alter vascular microstructure of the tissues, changing their permeability for the nanoparticles, or interfere with the proliferation or functioning of nanoparticle-capturing immune cells. Indeed, VCR has been reported to alter liver microstructure [37, 38] and inhibit phagocytosis in vitro [39] .
In order to study the factors influencing the biodistribution of VCR encapsulated into nanoparticles with release rates optimized for therapeutic applications (namely BIND-510 [19] ), we have obtained biodistribution data for the 16/5 PLA-PEG VCR-loaded nanoparticles (formulation T in Table 2 ) and conventional VCR and attempted to describe the distribution of VCR and nanoparticles using physiologybased pharmacokinetic modelling approaches.
Biodistribution of formulation T was assessed at the same nanoparticle doses as used in the experiment with ultra-slow release nanoparticles: 30, 70 and 140 mg/kg, which translates into 2.0, 4.6 and 9.2 mg/kg VCR, respectively. Biodistribution of conventional VCR sulphate was studied at injected doses of 1.5 and 3.0 mg/kg. In MX-1 tumor-bearing mice, the maximum tolerated dose levels (MTDs) for VCR in nanoparticle (formulation T) and sulphate forms were previously found to be 3.0 and 1.5 mg/kg, respectively [19] .
Contrary to ultra-slow release nanoparticles, conventional VCR and Formulation T caused dose-dependent whole body and organ weight loss in mice, with spleen mass particularly affected (Fig. S7) . There was no weight loss in the group dosed with 30 mg/kg Formulation T nanoparticles (2.0 mg/kg VCR), but mice injected with higher doses (above previously measured MTD) did lose weight proportionally to the injected dose (Fig. S2) . The latter was expected, given the injected VCR amounts and the release of 50% of encapsulated VCR over 24 h measured in vitro for Formulation T (Table S1 ).
Tissue pharmacokinetics of VCR encapsulated into Formulation T were in general similar to the pharmacokinetics of 16/5 nanoparticles (Formulations U16c/p), but had significant deviations from dose-linearity. As the injected dose increased, elimination of total VCR from plasma slowed down: elimination half-lifes were 9.7 h at nanoparticle dose of 30 mg/kg, 14.5 h at 70 mg/kg and 35.6 h at 140 mg/kg, while V d0 values were 70, 66 and 77 ml/kg, respectively. Elimination of total VCR from lungs also slowed down, normalized uptake increased in spleen, tumor and kidneys and decreased in the liver (Fig. 3) . Discrepancy between normalized uptake levels for different doses were most prominent at late timepoints (24 h and 48 h). Likewise, the total fraction of injected dose found in the six investigated tissues was similar for the three injected dose levels at 2 h post-injection (63-73%), but diverged by 48 h, reaching 16% for 30 mg/kg, 23% for 70 mg/kg and 36% for 140 mg/kg (Fig. S6) .
The distortion of normalized concentrations by changes in body and organ weights of the test animals in middle and high-dose groups could not explain the loss of dose-linearity in the biodistribution of Formulation T. Relative changes in body and organ weights did not exceed one third for the most affected animals (Figs. S2 and S6), while normalized concentrations differed as much as 4-fold between the lowest and highest doses (e.g. for spleen at 48 h post-injection). Also, the weight of investigated organs either stayed the same or decreased; this could explain the apparent increase in normalized concentrations for organs like spleen but not the apparent decrease in normalized concentrations for organs like liver.
Observed results were also unlikely to be explained by the differences in the release rate in the buffer solution in vitro and in the plasma and interstitial fluid of a living mouse, as no changes in release rate could explain the finding that at the highest injected dose of Formulation T the elimination of VCR from the bloodstream was slower than the elimination of Formulations U16c/p at the same dose (halflives of 35.6 h and 11.6 h, respectively).
On the other hand, the degree of discrepancy between the biodistribution of ultra-slow release nanoparticles and Formulation T was the highest for the highest injected dose, which was also the most toxic judging by body weight loss in mice. Thus we hypothesized that the observed loss of dose-linearity could be the result of VCR's toxic action interfering with normal distribution and clearance processes.
In order to find out whether we could explain the observed results for the Formulation T only in terms of nanoparticle and drug distribution and drug release from the nanoparticles without introducing toxic effects of the drug, we have performed mathematical modelling of our biodistribution data relating to the distribution of 16/5 PLA-PEG nanoparticles, conventional VCR and Formulation T after a single bolus injection in tumor-bearing mice. 
Mathematical modelling
We developed a physiologically based pharmacokinetic model of nanoparticle and encapsulated drug biodistribution in mice. Distribution of nanoparticles and drug was described in terms of their transfer between compartments representing plasma, relevant organs (tumor, liver, spleen, kidneys and lungs) and the rest of body (Fig. 4) . The buildup of the model, including the equations describing the transfer of nanoparticles and drug between compartments and drug release from the nanoparticles, is described in detail in the Supplementary material. The data on the biodistribution of 16/5 nanoparticles (Formulations U16c/p) and conventional VCR (Figs. 5, S7 and S8) were fitted well by the employed model, demonstrating that the biodistribution of both 16/ 5 nanoparticles in the dose range 30-140 mg/kg and conventional VCR in the dose range 1.5-3 mg/kg could be described in terms of first-order non-saturable distribution processes.
Using the parameter sets obtained for 16/5 nanoparticles and free VCR we have attempted to predict the biodistribution of Formulation T. For the lowest injected dose (30 mg/kg nanoparticle, 3 mg/kg VCR), the predictions of total VCR concentrations in tissues and plasma reasonably agreed with the experimental data, but for middle and high doses the predicted values underestimated VCR levels in plasma, tumor, kidneys and spleen and overestimated VCR levels in the liver (Fig. S11) .
Re-estimation of the nanoparticle distribution parameters using a united dataset consisting of formulation U and formulation T biodistribution data did not eliminate the discrepancies between experimental and best-fit concentrations of total VCR for T (Fig. S12) . However, after the introduction of a simple term describing the systemic toxicity of the released VCR (see Supplementary, we hypothesized that VCR toxicity slows down the diffusion of nanoparticles between plasma and tissues) the model and the experimental data for middle and high doses of T improved drastically (final result is shown in Figs. 5 and S13). It should be noted, though, that for the highest injected dose, simulated VCR concentrations in spleen, lungs and plasma at 48 h post-injection were still about 2-fold lower than experimentally measured concentrations, reflecting the incompleteness of the model and the involvement of some other, yet unexplained processes at this dose level.
These results suggest that the physiological effect (e.g. toxicity) of the encapsulated drug can be a non-negligible factor influencing the biodistribution of both the drug and the nanoparticle. However, if the therapeutic window of the encapsulated drug is wide enough, treatments can be developed using dosing ranges where the influence of the toxicity on biodistribution is limited.
Conclusions
In this study we have extensively investigated the factors influencing the biodistribution of PLA-PEG nanoparticles and payload in rats and mice in order to characterize PLA-PEG nanoparticles as a platform for drug delivery.
The dose-linearity and the absence of saturation effects in nanoparticle biodistribution at injected doses of up to 140 mg/kg demonstrates the predictability of this platform. In accordance with the expectations, the degree of PEGylation is an important factor determining the "stealthiness" of PLA-PEG nanoparticles: nanoparticles containing less PEG are more prone to elimination from the blood stream by the organs of the reticuloendothelial system, resulting in less delivery to the intended site of action.
Gradual changes in the nanoparticle-encapsulated drug biodistribution observed in response to gradual changes in the release rate of nanoparticle formulations are evidence of the platform's flexibility and controllability.
We found that systemic toxicity of the API released from the nanoparticles can influence the biodistribution of both API and nanoparticles, which is a point to consider for therapeutic formulations, where the API is administered in doses that have an effect on the treated subject. However, if the injected dose is known to have low or no toxicity, it may be possible to extrapolate the biodistribution of the encapsulated API from the distribution kinetics of nanoparticles and free API: in this work, focusing on vincristine-loaded formulations, such extrapolation has worked for the lowest injected drug dose.
